CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy

By Teft Wendy  

Breast Cancer Research and Treatment, Vol. 139, Iss. 1, 2013-05 ,pp. : 95-105

Springer Publishing Company

Access to resources Recommend Favorite

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice

By Ruddy Kathryn   Desantis Stephen   Gelman Rebecca   Wu Alan   Punglia Rinaa   Mayer Erica   Tolaney Sara   Winer Eric   Partridge Ann   Burstein Harold  

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 421-427

Springer Publishing Company

Access to resources Recommend Favorite

Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence

By Azoulay Laurent  

Breast Cancer Research and Treatment, Vol. 126, Iss. 3, 2011-04 ,pp. : 695-703

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 17, Iss. 13, 2018-01 ,pp. : 1805-1813

Bentham Science Publishers

Access to resources Recommend Favorite

Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen

By Siegelmann-Danieli Nava  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 505-510

Springer Publishing Company

Access to resources Recommend Favorite